Introduction
The rapidly growing incidence of obesity worldwide is alarming because it is a major cause of morbidity and mortality. Obesity increases the risk of developing serious complications, including type 2 diabetes mellitus, hypertension, steatohepatitis, fatty liver, and dyslipidemia (1) . Fatty liver is characterized by excessive triglyceride (TG) accumulation in the liver and is one of the most common forms of liver disease associated with obesity (2) . Obesity alters hepatic metabolism as well as cytokine and growth factor production, which contribute to the development of obesity-associated complications. In a mouse model of high-fat diet-induced obesity, the Wnt/β-catenin signaling pathway was demonstrated to regulate hepatic metabolism (3) . In contrast, in another study, liver-specific β-catenin knockout mice revealed increased susceptibility to methionine-and cholinedeficient diet-induced steatohepatitis (4) . These reports suggest that this pathway plays an important role in hepatic metabolism.
Leukocyte cell-derived chemotaxin 2 (LECT2) is one of the proteins regulated by hepatic β-catenin (5) and is primarily expressed by hepatocytes (6, 7) . It was initially identified in vitro as a neutrophil chemotactic factor (8) . More recently, functional studies have reported that LECT2 may function in immunological events such as hepatitis (9) and arthritis (10) , antihepatocarcinogenesis (11, 12) , and the negative regulation of the Wnt receptor signaling pathway in the small intestine (13) . There is accumulating evidence indicating that LECT2 is a pleiotropic protein, as are many cytokines; however, the possible involvement of LECT2 in metabolic diseases has not been investigated.
The aim of the present study was to determine whether serum LECT2 levels may be affected by obesity and its related diseases such as fatty liver. We developed a highly sensitive enzyme-linked immunosorbent assay (ELISA) protocol to evaluate the association between serum LECT2 levels and anthropometric or clinical variables. Moreover, this study sought to provide evidence that LECT2 is specific for metabolic diseases and is not a predictor of other disorders such as chronic kidney disease (CKD).
Materials and Methods

Study subjects
The study included 231 Japanese subjects (113 males and 118 females; aged 40-69 years) who visited the Department of General Medicine at the National Center for Global Health and Medicine (Tokyo, Japan) between August 2010 and September 2012 for an annual health check-up. Subjects were categorized into obese [waistto-height ratio (W/Ht) ≥ 0.5, n = 113] and lean (W/Ht < 0.5, n = 118) groups. The subjects receiving medication for diabetes mellitus, hypertension, or dyslipidemia or those with a provisional diagnosis of diabetes mellitus [fasting plasma glucose ≥ 126 mg/dL or hemoglobin A 1c (HbA1c) ≥ 6.5%] were excluded. This study was conducted with the approval from the ethical committee of the National Center for Global Health and Medicine. Written informed consent was obtained from each subject prior to study enrollment.
Data collection
Anthropometric measurements and blood sampling were performed after overnight fasting (for at least 12 h). Waist circumference (WC) at the level of the umbilicus and hip circumference at the level of the maximum protuberance of the buttocks were recorded with a measuring tape. Body mass index (BMI), waist-to-hip ratio (WHR), and W/Ht were calculated using the anthropometric measures. For the insulin resistance index, the homeostasis model assessment ratio (HOMA-R) was calculated from fasting plasma glucose (FPG) and fasting insulin values using the following equation: HOMA-R = [FPG (mg/dL) × fasting insulin (mU/L)]/405. A physician documented the medical history and alcohol consumption during a personal interview. A diagnosis of fatty liver was made on the basis of the results of an abdominal ultrasound performed by trained technicians. Fatty liver was defined as liver parenchyma with echogenicity higher than that of the kidney cortex, the presence of vascular blurring, and deep attenuation of ultrasound waves (14) . Subjects were assessed for kidney disease by calculating the estimated glomerular filtration rate (eGFR) according to the Japanese formula using serum creatinine (SCr) (15) . A diagnosis of CKD was made if eGFR was < 60 mL/ min/1.73 m 2 (16).
Measurement of serum LECT2 by ELISA
The serum LECT2 levels were measured using a commercially available ELISA kit (Ab-Match ASSEMBLY Human LECT2 Kit with Ab-Match UNIVERSAL Kit; Medical & Biological Laboratories, Nagoya, Japan) with modifications to improve sensitivity. The LECT2 standard and serum samples (1:10 dilution) were diluted with sample diluent (provided with the kit) in the presence of 300 mM NaCl, which is an optimal concentration for sensitivity (Table S1 , http://www.biosciencetrends. com/docindex.php?year=2013&kanno=6). These samples were incubated for 60 min at room temperature before adding to an ELISA plate. These conditions consistently generated LECT2 values that were 2-fold higher than those of the standard protocol (Table  S2 , http://www.biosciencetrends.com/docindex. php?year=2013&kanno=6).
Statistical analyses
The results were presented as mean ± standard deviation (S.D. Table 1) . Analysis of the anthropomorphic parameters revealed significantly lower BMI, WC, and WHR in females (p < 0.001). The mean systolic and diastolic blood pressures were within the normal range but significantly higher in males. With regard to systemic disease, there was no significant gender difference in the CRP levels. However, there were gender differences with regard to white blood cell counts. The other parameters were selected to characterize the subject population with regard to diabetes/obesity, dyslipidemia/fatty liver, and CKD. None of the subjects were diagnosed with diabetes mellitus. However, half of the subjects were classified as obese on the basis of W/Ht ≥ 0.5 (17), with a higher occurrence rate in males. With regard to liver diseases, the levels of AST, ALT, and γ-GTP were slightly higher in males. These findings are consistent with the fact that approximately 36% subjects were diagnosed with fatty liver, with a 2-fold higher incidence observed in males than females. Overall, these findings are consistent with rank correlation coefficient. A partial correlation was used to evaluate these relationships, independent of the other variables. With regard to stepwise multiple linear regression analysis, because the levels of TG, high-density lipoprotein (HDL) cholesterol, C-reactive protein (CRP), aspartate transaminase (AST), alanine transaminase (ALT), and γ-glutamyl transpeptidase (γ-GTP) were not normally distributed, logarithmic transformations were used to approach normal distribution and to obtain equal variances. p values < 0.05 were considered statistically significant.
Results
Clinical characteristics of the subjects
A total of 231 subjects were included in this study, which included approximately equal numbers of males (n = 113) and females (n = 118), who were in their mid 50s 
Impact of obesity on serum LECT2 levels
Serum LECT2 levels were comparable in males and females (43.6 ± 12.9 vs. 43.4 ± 14.3 ng/mL) with an overall average of 43.5 ± 13.6 ng/mL. The average LECT2 levels were 47.4 ± 13.1 ng/mL and 39.7 ± 13.1 ng/mL for the obese and lean subjects, respectively (p < 0.001). When the data were further segregated on the basis of gender, we observed similar effects in males (46.8 ± 11.9 vs. 39.5 ± 13.1 ng/mL, p = 0.002) and females (48.2 ± 14.6 vs. 39.8 ± 13.1 ng/mL, p = 0.001), respectively. These data suggest that serum LECT2 levels presented no gender difference and were higher in obese subjects. Therefore, we conducted regression analyses between serum LECT2 and the anthropometric parameters: BMI, WC, WHR, and W/Ht. All the four parameters positively correlated with serum LECT2 levels ( Figure 1 ). These data indicate that serum LECT2 levels increase in an obesity-dependent manner. The strongest correlation was observed between LECT2 and W/Ht adjusted for age and gender (r = 0.349, p < 0.001). As a result, W/Ht was subsequently employed as the sole anthropometric measure to simplify further analyses on obesity.
Impact of liver and kidney diseases on serum LECT2
Because several subjects were diagnosed with secondary complications of obesity, the Spearman's rank correlation analyses were conducted to determine whether LECT2 associations were selective for clinical parameters indicative of hypertension, inflammation, diabetes mellitus, dyslipidemia, liver diseases, or kidney disease (Table 2 ). Among the markers of obesity, high LECT2 levels simply correlated with CRP and AST levels only in males, and with HbA1c, LDL cholesterol, BUN, and SCr levels only in females. In addition, a positive correlation was observed between LECT2 and the markers of diabetes mellitus, dyslipidemia, liver disease, and kidney disease. These included, insulin, HOMA-R, TG, HDL cholesterol, ALT, γ-GTP, and uric acid (UA). These correlations suggest that high serum LECT2 levels are associated with the development of liver and kidney diseases.
Multiple linear regression analysis of serum LECT2 levels
All the parameters having significant simple correlation with LECT2 for at least one gender (Table 2) were assessed for an independent relationship with LECT2 (CRP, HbA1c, insulin, HOMA-R, TG, HDL cholesterol, LDL cholesterol, AST, ALT, γ-GTP, UA, BUN, and SCr) as well as age and W/Ht. These multiple linear regression analyses were performed with serum LECT2 as a dependent variable for each gender (Table 3 ). In males, γ-GTP, TG, and age remained significant determinant of serum LECT2. On the other hand, in females, HOMA-R, BUN, HDL cholesterol, and γ-GTP were observed to significantly contribute to the determinant of serum LECT2 levels. These multiple regression analyses indicate that serum LECT2 is associated not only with obesity but also with liver diseases in both genders and with kidney dysfunction in females. In addition, these findings suggested that γ-GTP levels were strongly associated with serum LECT2 levels. We considered that this observation may arise if the serum LECT2 levels were also correlated with alcohol consumption. Therefore, we analyzed whether serum LECT2 and γ-GTP levels were correlated with alcohol consumption. Spearman's rank correlation analysis showed that serum LECT2 levels were not statistically correlated with alcohol consumption (ρ = 0.065, p = 0.327 in males, ρ = −0.064, p = 0.488 in females), whereas γ-GTP level was positively correlated with alcohol consumption in both genders (ρ = 0.363, p < 0.001 in males, ρ = 0.193, p = 0.037 in females). These results suggest that an increase in serum LECT2 level does not directly reflect liver damage due to alcohol abuse. When the 231 subjects were divided on the basis of the diagnosis of fatty liver, the average LECT2 levels were 48.7 ± 13.6 ng/mL and 40.5 ± 12.8 ng/mL in subjects with and without fatty liver (p < 0.001), respectively. When categorized on the basis of gender, the average LECT2 levels were 46.8 ± 12.8 ng/mL and 40.4 ± 12.3 ng/mL (p = 0.007) in males with and without fatty liver, respectively, and 52.6 ± 14.7 ng/ mL and 40.6 ± 13.1 ng/mL (p < 0.001) in females with and without fatty liver, respectively. However, no statistically significant difference was observed when the subjects were divided into a CKD group (48.1 ± 14.4 ng/mL) and a non-CKD group (43.0 ± 13.5 ng/ mL) according to eGFR, even separated by gender (45.1 ± 12.9 ng/mL and 43.5 ± 13.0 ng/mL in males, 50.0 ± 15.5 ng/mL and 42.6 ± 14.1 ng/mL in females). Taken together, these results suggest that high serum LECT2 levels may indicate higher risks of developing obesityrelated liver diseases.
Receiving operating characteristic curve analyses
Considering the relationships established between LECT2 levels and the markers of obesity and fatty liver, receiver operating characteristic (ROC) curve analysis was performed to check whether serum LECT2 levels could discriminate between lean and obese subjects, and subjects without and with fatty liver (Table 4) . With regard to obesity, the area under curve (AUC) values for LECT2 levels were significant both in males (0.655, p = 0.002) and females (0.670, p < 0.001). The optimal cutoff values were 41.8 ng/mL (sensitivity, 71.4%; specificity, 62.0%) and 45.0 ng/mL (sensitivity, 64.0%; specificity, 72.1%) for males and females, respectively. Moreover, as presented in Table 4 , ROC curve analysis revealed that AUCs of LECT2 levels for fatty liver were 0.646 (p = 0.004) and 0.733 (p < 0.001) for males and females, respectively. From these data, the optimal cutoff values of 43.3 ng/mL (sensitivity, 67.9%; specificity, 59.7%) and 46.4 ng/mL (sensitivity, 70.4%; specificity, 69.2%) were determined for males and females, respectively. Overall, these results indicated that serum LECT2 levels have predictive values with regard to the occurrence of obesity and fatty liver.
Discussion
The worldwide obesity epidemic is raising concerns because of the serious complications developing in these patients, including cardiovascular disease, diabetes mellitus, and liver diseases. In fact, the development of better preventive measures based on education and early detection and diagnosis have become a priority in the medical community. Unfortunately, the best predictors of obesity are anthropometric measures, which do not take the obesity-related complications into account. The present study demonstrates, for the first time, that serum LECT2 levels positively correlate with the markers of obesity and fatty liver.
The sensitivity of the ELISA assay currently available for serum LECT2 is too low to distinguish between different patient populations. Studies using this ELISA protocol reported the presence of LECT2 levels in human serum or plasma in the range of 1-15 ng/mL (18) (19) (20) . Recently, Ando et al. reported LECT2 levels of 19.7 ± 3.4 ng/mL in heparinized plasma from healthy volunteers with the conventional ELISA protocol (21) . In addition, we preliminarily determined that the serum LECT2 levels measured by conventional ELISA were lower than the estimated levels obtained by immunoblotting using recombinant LECT2 protein as a standard (data not revealed). These studies suggested that electrostatic interactions with other serum proteins may interfere with the LECT2 assay. One such candidate protein is transferrin, whose interaction with LECT2 has been reported in fish and mice (22) . Another candidate protein is LECT2 itself, which can oligomerize in vitro under certain conditions as previously reported (23) . Therefore, we resolved the electrostatic interference by adding 300 mM NaCl to the sample diluent, which increased the sensitivity of the assay by more than 2-fold. Using this modified protocol, we report overall LECT2 levels of 43.5 ± 13.6 ng/mL in human serum in a subject group representative of the general Japanese population. When the 231 subjects included in the present study were segregated on the basis of a diagnosis of obesity or fatty liver, the average LECT2 levels were 47.4 ± 13.1 ng/mL vs. 39.7 ± 13.1 ng/mL in the obese and lean subjects, respectively, and 48.7 ± 13.6 ng/mL vs. 40.5 ± 12.8 ng/mL in subjects with and without fatty liver, respectively. The fact that differences between these values were statistically significant testifies to the high sensitivity of this modified ELISA assay. These results indicate a positive correlation between serum LECT2 levels and obesity and fatty liver.
Simple regression analysis established a positive correlation between serum LECT2 and all the four major anthropometric measures of obesity: BMI, WC, WHR, and W/Ht. In addition, the ROC analysis revealed the predictive accuracy of obesity detection in both genders. The hepatic Wnt/β-catenin signaling pathway plays an important role in the metabolism of hepatic glucose, glycogen, and lipids (3). Together with the Wnt/β-catenin signaling pathway that increases LECT2 expression (5), these studies and the present data are comparable with regard to the notion that LECT2 participates in the events leading to obesity.
The LECT2 levels of the subjects with fatty liver were significantly higher compared with those in the subjects without fatty liver. Moreover, the ROC curve analysis showed that serum LECT2 levels significantly discriminated between subjects with and without fatty liver in both genders. In addition, these data are consistent with the studies reporting an increase in hepatic CYP2E1 in obesity (24) and fatty liver (25) , which is a direct hepatic β-catenin target gene as well as LECT2 gene (5) . In addition, insulin resistance is promoted and plays a key role during the progression of a nonalcoholic fatty liver disease. HOMA-R, an indicator of insulin resistance, was correlated with serum LECT2 levels. Therefore, further studies are proposed to investigate the association between serum LECT2 levels and steatohepatitis, cirrhosis, and hepatocarcinoma.
Furthermore, LECT2 levels were associated with the kidney disease-related factors UA, BUN, and SCr. However, in this study, LECT2 could not be determined as a predictor of renal function. These findings are supportive evidence that LECT2 is specific for obesity and obesity-related liver disease.
In conclusion, this study demonstrates that the more sensitive ELISA protocol, which we developed for human serum LECT2, will now allow discriminative studies among different patient populations. Using this assay, we demonstrated that serum LECT2 levels vary between subjects diagnosed with obesity and fatty liver. This clinical study may lead to the development of a new population screening strategy for the worldwide obesity epidemic and its major secondary complications.
